Enhanced cancer-targeted delivery using engineered high-density lipoprotein-based nanocarriers

Ian R. Corbin, Juan Chen, Weiguo Cao, Hui Li, Sissel Lund-Katz, Gang Zheng

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

One of the greatest obstacles nanoscale drug delivery systems face is the high nonspecific uptake by the reticular endothelial system (RES). Currently, PEGylation is the method of choice to address this problem. Herein we introduce an engineered high density lipoprotein-based nanocarrier (eHDL) as an enhanced cancer-targeted delivery system. eHDLs are high-density lipoprotein (HDL)-like nanoparticles consisting of a tumor ligand-conjugated apoA-I scaffold capable of carrying versatile payloads of cancer diagnostics and therapeutics. Similar to native HDL, eHDLs are biocompatible, precisely controlled ultra small particles (∼10 nm) with RES mitigating properties. In this study, we describe the preparation and characterization of eHDL and confirm that incorporation of exogenous agents do not compromise the structural or functional integrity of the particle. We further demonstrate both in vitro and in vivo that eHDL can be efficiently targeted to cancer cells. Proof of the efficacy of this procedure was demonstrated using a proto-type near-infrared (NIR) fluorescent-labeled folate receptor-targeted eHDL. This eHDL displayed exceptional in vivo performance in tumor-bearing mice. High levels of the particles were selectively localized within the targeted tumor while minimal uptake by RES was detected. This study demonstrates that eHDL particles are highly efficient carriers that provide a viable non-PEGylated approach for addressing the non-specific uptake of most nanoparticle-based delivery systems.

Original languageEnglish (US)
Pages (from-to)367-376
Number of pages10
JournalJournal of Biomedical Nanotechnology
Volume3
Issue number4
DOIs
StatePublished - Dec 2007

Fingerprint

Lipoproteins
HDL Lipoproteins
Neoplasms
Tumors
Nanoparticles
Bearings (structural)
Apolipoprotein A-I
Drug Delivery Systems
Folic Acid
Scaffolds
Ligands
Cells
Infrared radiation

Keywords

  • Cancer
  • Lipoprotein
  • Nanoparticle
  • Near-infrared fluorescence imaging
  • Reticular endothelial system

ASJC Scopus subject areas

  • Materials Science(all)
  • Bioengineering
  • Biomedical Engineering
  • Medicine (miscellaneous)
  • Pharmaceutical Science

Cite this

Enhanced cancer-targeted delivery using engineered high-density lipoprotein-based nanocarriers. / Corbin, Ian R.; Chen, Juan; Cao, Weiguo; Li, Hui; Lund-Katz, Sissel; Zheng, Gang.

In: Journal of Biomedical Nanotechnology, Vol. 3, No. 4, 12.2007, p. 367-376.

Research output: Contribution to journalArticle

Corbin, Ian R. ; Chen, Juan ; Cao, Weiguo ; Li, Hui ; Lund-Katz, Sissel ; Zheng, Gang. / Enhanced cancer-targeted delivery using engineered high-density lipoprotein-based nanocarriers. In: Journal of Biomedical Nanotechnology. 2007 ; Vol. 3, No. 4. pp. 367-376.
@article{e243fc0d511f4482a8af88bc9446b7fa,
title = "Enhanced cancer-targeted delivery using engineered high-density lipoprotein-based nanocarriers",
abstract = "One of the greatest obstacles nanoscale drug delivery systems face is the high nonspecific uptake by the reticular endothelial system (RES). Currently, PEGylation is the method of choice to address this problem. Herein we introduce an engineered high density lipoprotein-based nanocarrier (eHDL) as an enhanced cancer-targeted delivery system. eHDLs are high-density lipoprotein (HDL)-like nanoparticles consisting of a tumor ligand-conjugated apoA-I scaffold capable of carrying versatile payloads of cancer diagnostics and therapeutics. Similar to native HDL, eHDLs are biocompatible, precisely controlled ultra small particles (∼10 nm) with RES mitigating properties. In this study, we describe the preparation and characterization of eHDL and confirm that incorporation of exogenous agents do not compromise the structural or functional integrity of the particle. We further demonstrate both in vitro and in vivo that eHDL can be efficiently targeted to cancer cells. Proof of the efficacy of this procedure was demonstrated using a proto-type near-infrared (NIR) fluorescent-labeled folate receptor-targeted eHDL. This eHDL displayed exceptional in vivo performance in tumor-bearing mice. High levels of the particles were selectively localized within the targeted tumor while minimal uptake by RES was detected. This study demonstrates that eHDL particles are highly efficient carriers that provide a viable non-PEGylated approach for addressing the non-specific uptake of most nanoparticle-based delivery systems.",
keywords = "Cancer, Lipoprotein, Nanoparticle, Near-infrared fluorescence imaging, Reticular endothelial system",
author = "Corbin, {Ian R.} and Juan Chen and Weiguo Cao and Hui Li and Sissel Lund-Katz and Gang Zheng",
year = "2007",
month = "12",
doi = "10.1166/jbn.2007.053",
language = "English (US)",
volume = "3",
pages = "367--376",
journal = "Journal of Biomedical Nanotechnology",
issn = "1550-7033",
publisher = "American Scientific Publishers",
number = "4",

}

TY - JOUR

T1 - Enhanced cancer-targeted delivery using engineered high-density lipoprotein-based nanocarriers

AU - Corbin, Ian R.

AU - Chen, Juan

AU - Cao, Weiguo

AU - Li, Hui

AU - Lund-Katz, Sissel

AU - Zheng, Gang

PY - 2007/12

Y1 - 2007/12

N2 - One of the greatest obstacles nanoscale drug delivery systems face is the high nonspecific uptake by the reticular endothelial system (RES). Currently, PEGylation is the method of choice to address this problem. Herein we introduce an engineered high density lipoprotein-based nanocarrier (eHDL) as an enhanced cancer-targeted delivery system. eHDLs are high-density lipoprotein (HDL)-like nanoparticles consisting of a tumor ligand-conjugated apoA-I scaffold capable of carrying versatile payloads of cancer diagnostics and therapeutics. Similar to native HDL, eHDLs are biocompatible, precisely controlled ultra small particles (∼10 nm) with RES mitigating properties. In this study, we describe the preparation and characterization of eHDL and confirm that incorporation of exogenous agents do not compromise the structural or functional integrity of the particle. We further demonstrate both in vitro and in vivo that eHDL can be efficiently targeted to cancer cells. Proof of the efficacy of this procedure was demonstrated using a proto-type near-infrared (NIR) fluorescent-labeled folate receptor-targeted eHDL. This eHDL displayed exceptional in vivo performance in tumor-bearing mice. High levels of the particles were selectively localized within the targeted tumor while minimal uptake by RES was detected. This study demonstrates that eHDL particles are highly efficient carriers that provide a viable non-PEGylated approach for addressing the non-specific uptake of most nanoparticle-based delivery systems.

AB - One of the greatest obstacles nanoscale drug delivery systems face is the high nonspecific uptake by the reticular endothelial system (RES). Currently, PEGylation is the method of choice to address this problem. Herein we introduce an engineered high density lipoprotein-based nanocarrier (eHDL) as an enhanced cancer-targeted delivery system. eHDLs are high-density lipoprotein (HDL)-like nanoparticles consisting of a tumor ligand-conjugated apoA-I scaffold capable of carrying versatile payloads of cancer diagnostics and therapeutics. Similar to native HDL, eHDLs are biocompatible, precisely controlled ultra small particles (∼10 nm) with RES mitigating properties. In this study, we describe the preparation and characterization of eHDL and confirm that incorporation of exogenous agents do not compromise the structural or functional integrity of the particle. We further demonstrate both in vitro and in vivo that eHDL can be efficiently targeted to cancer cells. Proof of the efficacy of this procedure was demonstrated using a proto-type near-infrared (NIR) fluorescent-labeled folate receptor-targeted eHDL. This eHDL displayed exceptional in vivo performance in tumor-bearing mice. High levels of the particles were selectively localized within the targeted tumor while minimal uptake by RES was detected. This study demonstrates that eHDL particles are highly efficient carriers that provide a viable non-PEGylated approach for addressing the non-specific uptake of most nanoparticle-based delivery systems.

KW - Cancer

KW - Lipoprotein

KW - Nanoparticle

KW - Near-infrared fluorescence imaging

KW - Reticular endothelial system

UR - http://www.scopus.com/inward/record.url?scp=45849128001&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45849128001&partnerID=8YFLogxK

U2 - 10.1166/jbn.2007.053

DO - 10.1166/jbn.2007.053

M3 - Article

AN - SCOPUS:45849128001

VL - 3

SP - 367

EP - 376

JO - Journal of Biomedical Nanotechnology

JF - Journal of Biomedical Nanotechnology

SN - 1550-7033

IS - 4

ER -